The Meningitis Belt of Africa has long been grappling with the burden of pneumococcal and meningococcal diseases, posing substantial threats to public health. Africa has the largest burden of bacterial meningitis, bearing approximately half of the 1.2 million annual cases that occur globally. Ghana reports seasonal cyclical meningitis outbreaks almost every year with an approximate 30 million at risk despite vaccine deployments within the country. Recognizing the urgency of the situation, Nigeria's vaccination drive signifies a significant step towards curbing the spread of this disease.
Map of the African Meningitis Belt
Historical Context and Challenges
Polysaccharide vaccines had been used to control African meningitis epidemics for >30 years but with little or modest success, largely because of logistical problems in the implementation of reactive vaccination campaigns that are begun after epidemics are under way. Carriage surveys and enhanced disease surveillance have historically played a crucial role in early detection, prevention, and control of such diseases. In a landmark move, Nigeria has become the first country globally to introduce a groundbreaking vaccine called Men5CV, recommended by the World Health Organization (WHO). This vaccine targets five strains of meningococcus bacteria, offering comprehensive protection against this deadly disease.
WHO's Response and Collaborative Efforts
WHO accepted the challenge and created a project called Epidemic Meningitis Vaccines for Africa (EVA) that served as an organizational framework for external consultants, PATH, the US Centers for Disease Control and Prevention (CDC), and the Bill & Melinda Gates Foundation (BMGF). Consultations were initiated with major vaccine manufacturers. EVA commissioned a costing study/business plan for the development of new group A or A/C conjugate vaccines and explored the feasibility of developing these products as a public-private partnership. Representatives from African countries were consulted. They confirmed that the development of conjugate vaccines was a priority and provided information on preferred product characteristics.
The expert consultations recommended that a group A meningococcal conjugate vaccine be developed and introduced into the African meningitis belt. In June 2001, BMGF awarded a grant of US$70 million to create the Meningitis Vaccine Project (MVP) as a partnership between PATH and WHO, with the specific goal of developing an affordable MenA conjugate vaccine to eliminate MenA meningitis epidemics in Africa.
Read also: Experience Fad's Fine African Cuisine
The Breakthrough Men5CV Vaccine
The innovative Men5CV vaccine offers a revolutionary defense against five major meningococcal strains, surpassing the capabilities of existing vaccines, which primarily target a single strain. By leveraging cutting-edge technology and a collaborative effort between PATH and the Serum Institute of India, this vaccine represents a pivotal achievement in global health.
WHO's prequalification of Men5CV and subsequent endorsement paved the way for its introduction, supported by Gavi's resources allocated for outbreak response and mass preventive campaigns, scheduled to commence in 2025 across Meningitis Belt countries. The initiative, funded by Gavi, the Vaccine Alliance, aims to address Nigeria's status as one of the 26 African nations within the Meningitis Belt, where meningitis outbreaks are prevalent.
The rollout of one million vaccines in Nigeria marks a crucial step towards achieving global health goals, including the defeat of meningitis by 2030. Last year, Africa witnessed a 50% surge in meningitis cases, prompting urgent action. A severe outbreak of Neisseria meningitidis serogroup C in Nigeria resulted in numerous cases and fatalities, prompting swift action through a vaccination campaign targeting over a million individuals aged 1-29 years.
How Men5CV Works
The newly introduced Men5CV vaccine offers broad protection against five major meningococcal strains, including A, C, W, Y, and X, in a single shot, surpassing the capabilities of previous vaccines limited to targeting a single strain. Developed over 13 years through a partnership between PATH and the Serum Institute of India, this vaccine represents a significant advancement in global health.
WHO's endorsement of Men5CV, coupled with Gavi's support, underscores the importance of international cooperation in addressing public health challenges. Through strategic partnerships and proactive measures, Nigeria aims to eliminate meningitis and safeguard the well-being of its population.
Read also: The Story Behind Cachapas
Why is meningitis so dangerous? - Melvin Sanicas
Nigeria's Pioneering Role
In a groundbreaking achievement, Nigeria has initiated the world's first rollout of a new vaccine known as Men5CV, endorsed by the World Health Organization (WHO). Funded by Gavi, the Vaccine Alliance, this initiative aims to combat meningitis, particularly prevalent in Nigeria, located within the African Meningitis Belt alongside 25 other hyper-endemic countries.
Health workers have initiated an extensive immunization campaign with the goal of reaching one million individuals, underscoring the commitment to widespread vaccination efforts. The success of Men5CV in Nigeria signifies a transformative era in meningitis prevention, reflecting the culmination of collaborative efforts and innovative partnerships.
Additional Strategies and Findings
Navrongo, situated in the Northern part of Ghana and some parts of the Middle Belt of Ghana, has been identified as key target areas for surveillance in Ghana. A total of 2932 study participants were enrolled and assessed for the carriage of meningococcus. The study showed that carriage of the meningococcus was significantly high within the study population, particularly among young age groups despite vaccine deployment within the country.
Antibiotic Prophylaxis Study
Village-wide distribution of single-dose oral ciprofloxacin within 72 hours of case notification reduced overall meningitis AR. After the emergence of NmC, and in the presence of an insufficient quantity of vaccine against this serogroup, a WHO expert panel recommended a trial of antibiotic prophylaxis with ciprofloxacin for household contacts of meningitis cases during an outbreak in the meningitis belt.
Between April 22 and May 18, 2017, 49 villages were included: 17 to the control arm, 17 to household prophylaxis, and 15 to village-wide prophylaxis. A total of 248 cases were notified in the study after the index cases. The AR was 451 per 100,000 persons in the control arm, 386 per 100,000 persons in the household prophylaxis arm (t test versus control p = 0.68), and 190 per 100,000 persons in the village-wide prophylaxis arm (t test versus control p = 0.032).
Read also: Techniques of African Jewellery
Village-wide distribution of single-dose oral ciprofloxacin within 72 hours of case notification reduced overall meningitis AR. Citation: Coldiron ME, Assao B, Page A-L, Hitchings MDT, Alcoba G, Ciglenecki I, et al.
Socioeconomic and Environmental Factors
Socioeconomic and climate conditions are macro-determinants associated with BM cumulative incidence. Bacterial meningitis (mainly caused by N. meningitidis, H. influenzae type B, or S. pneumoniae), is a communicable disease associated with different climatological and social characteristics. A pattern of common origin with continuous exposition and seasonality of cases was observed. Socio-epidemiological determinants contributing to differentiating the AMB from the rest of Africa were household occupancy (OR 3.17 CI 95% 1.09-9.22, p = 0.034) and malaria incidence (OR 1.01 CI 95% 1.00-1.02, p = 0.016).
Although different studies have already demonstrated that socioepidemiological conditions are associated with BM in individuals from the AMB, one could question why the cumulative incidence importantly diverges between two Sub-Saharan countries that share land borders.
| Region | Cumulative Incidence (per 100,000 population) |
|---|---|
| West Africa | 111.93 |
| Central Africa | 87.23 |
| East Africa | 65.10 |
| North Africa | 42.47 |
The Path Forward
Moving forward, international cooperation remains essential in achieving the global roadmap to defeating meningitis by 2030, which entails eliminating bacterial meningitis epidemics, reducing cases and deaths by 50% and 70%, respectively, and improving quality of life post-meningitis. The forthcoming international summit on meningitis in Paris presents a pivotal opportunity for leaders to reaffirm their commitment towards this shared goal and accelerate progress towards a meningitis-free world.
Meningitis poses a grave threat, causing inflammation of the protective membranes surrounding the brain and spinal cord. Bacterial meningitis, the most severe form, can lead to death within hours if left untreated.
